The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be (link sends e-mail)
| Study Name on ClinicalTrials.gov (link is external) | Extention Study of ArikaceTM in CF Patients With Chronic Pseudomonas Aeruginosa Infection |
|---|---|
| Study Drug | ArikaceTM (Liposomal amikacin for inhalation) |
| Type of Study Drug | Anti-infective |
| Study Title | Long Term Safety and Tolerability of Open-Label Liposomal Amikacin for Inhalation (ArikaceTM) in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa |
| Study Phase | 3 |
| Study Sponsor | Insmed |
http://clinicaltrials.gov/ct2/show/record/NCT01316276 (link is external) | |
| Participating ECFS-CTN sites | Belgium: Leuven Denmark: Copenhagen UK: London, Birmingham, Nottingham Germany: Berlin, Frankfurt Spain: Barcelona Italy: Verona France: West-Paris (Cochin) |
| Age | 6 years and older |